natgillin/translations-raw huggingface dataset:
Cytokrom P450 Ciprofloxacin hæmmer CYP1A2 og kan derfor medføre øgede serumkoncentrationer af lægemidler, som gives samtidigt, og som metaboliseres af dette enzym (f. eks. teofyllin, clozapin, ropinirol og tizanidin).
137 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
139 Interaktioner med laboratorietests Ciprofloxacins in vitro- aktivitet over for Mycobacterium tuberculosis kan resultere i falsk negative bakteriologiske testresultater i prøver fra patienter, som tager ciprofloxacin.
Interaction with tests The in-vitro activity of ciprofloxacin against Mycobacterium tuberculosis might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.
Indhold af sukrose Da den orale suspension indeholder sukrose, må den ikke bruges til patienter med fruktoseintolerans, glukose- galaktose malabsorption eller sukrose- isomaltase- insufficiens.
Sucrose Load As the oral suspension contains sucrose, it should not be used in patients with fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase deficiency.
Ciprofloxacin 50 mg/ ml suspension indeholder 1, 4 g sukrose pr. måleske.
As Ciprofloxacin Bayer 50 mg/ mL suspension contains 1.4 g sucrose per 5-mL measuring spoonful, this has to be taken into consideration in terms of daily intake.
Det skal tages i betragtning i relation til det daglige indtag.
4.5 Interaction with other medicinal products and other forms of interaction
4. 5 Interaktion med andre lægemidler og andre former for interaktion Virkninger af andre lægemidler på ciprofloxacin:
Effects of other products on ciprofloxacin:
Methotrexat
138 Methotrexate
140 Andre xanthinderivativer
Other xanthine derivatives
Hos unge og prænatale dyr, som var udsat for quinoloner, er der set effekt på umodent bindevæv.
In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the
5. 3).
139 drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).
141 Nedenstående tabel angiver de bivirkninger, der er set ved ciprofloxacin i kliniske studier og under overvågning efter markedsføringen (oral, intravenøs og sekventiel behandling).
ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin Bayer (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below.
Organklasse
140 System Organ
1/ 1. 000
Psychiatric Disorders
< 1/ 10. 000
Psychotic reactions (see section 4.4)
(kan ikke
Nervous System Disorders
beregnes fra de foreliggende data) nedsat hørelse Hjerte
Visual disturbances Tinnitus Hearing loss / Hearing impaired
4. 4)
Rare
Hud og subkutane væv
Very Rare
Udslæt Pruritus Urticaria
Frequency
4. 4)
Class
Petekkier Erythema multiforme Erythema nodosum Stevens - Johnson - syndrom (potentielt livstruende) Toksisk epidermal nekrolyse (potentielt livstruende)
≥ 1/ 1 000 to <
Knogler, led, muskler og bindevæv
≥ 1/ 10 000 to <
Muskel - og skeletsmerter (f. eks. ekstremitetssmer - ter, rygsmerter og brystsmerter) Artralgier
< 1/ 10 000
Myalgier Artritis Øget muskeltonus og muskelkramper
not known
Muskelsvag - hed Tendinitis Seneruptur (fortrinsvis akillessenen) (se pkt.
to < 1/ 10
143
1/ 100
Organklasse
1/ 1 000
Almindelig ≥ 1/ 100 til < 1/ 10
(cannot be estimated from available data)
Ikke almindelig ≥ 1/ 1. 000 til < 1/ 100
Skin and Subcutaneous Tissue Disorders
Sjælden ≥ 1/ 10. 000 til < 1/ 1. 000
Rash Pruritus Urticaria
Meget sjælden < 1/ 10. 000 4. 4)
Photosensitivity reactions (see section 4.4)
Ukendt hyppihed (kan ikke beregnes fra de foreliggende data)
Musculoskeletal, Connective Tissue and Bone Disorders
Nyrer og urinveje
Musculoskeletal pain (e. g. extremity pain, back pain, chest pain) Arthralgia
Nedsat nyrefunktion
Myalgia Arthritis Increased muscle tone and cramping
Nyresvigt Hæmaturi
Renal and Urinary Disorders
Krystalluri (se pkt.
Renal impairment
4. 4) Tubulointerstitiel nephritis Almene symptomer og reaktioner på administra - tionsstedet
Renal failure Haematuria Crystalluria (see section 4.4) Tubulointerstitial nephritis
Det er indberettet, at en overdosis på 12 g har medført lette toksiske symptomer.
4.9 Overdose 142 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
S ≤ 0, 5 mg/ l S ≤ 0, 5 mg/ l S ≤ 1 mg/ l
S ≤ 0.5 mg/ L S ≤ 0.5 mg/ L S ≤ 1 mg/ L
R > 1 mg/ l R > 1 mg/ l R > 1 mg/ l
R > 1 mg/ L R > 1 mg/ L R > 1 mg/ L
S ≤ 1 mg/ l
S ≤ 1 mg/ L
R > 1 mg/ l
R
Staphylococcus spp. - breakpoints for ciprofloxacin refererer til højdosisbehandling. * Ikke- artsrelaterede breakpoints er primært blevet bestemt på grundlag af PK/ PD- data, og er uafhængige af fordelingerne af MIC for specifikke arter.
1 Staphylococcus spp. – breakpoints for ciprofloxacin relate to high dose therapy. * Non-species-related breakpoints have been determined mainly on the basis of PK/ PD data and are independent of MIC distributions of specific species.
ALMINDELIGE FØLSOMME ARTER Aerobe grampositive mikroorganismer Bacillus anthracis (1) Aerobe gramnegative mikroorganismer Aeromonas spp.
COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
144 Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae * Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
Propionibacterium acnes ORGANISMER MED NATURLIG RESISTENS Aerobe grampositive mikroorganismer Actinomyces
($):
Den maksimale. serumkoncentration nås efter 1- 2 timer.
145 Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.
Farmakokinetikken for ciprofloxacin oral suspension 50 mg/ ml og 100 mg/ ml ligner tabletternes farmakokinetik.
The pharmacokinetics of ciprofloxacin oral suspension 50 mg/ mL and 100 mg/ mL are similar to those of tablets.
Ciprofloxacin findes overvejende uioniseret i plasma og har i steadystate et stort distributionsvolumen på 2- 3 l/ kg legemsvægt.
Ciprofloxacin is present in plasma largely in a non- ionized form and has a large steady state distribution volume of 2-3 L/ kg body weight.
Der er fundet små koncentrationer af fire metabolitter, som blev identificeret som: desethylenciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) og
Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4).
Hos 10 børn med svær sepsis var Cmax 6, 1 mg/ l (område 4, 6- 8, 3 mg/ L) efter en 1- times intravenøs infusion i en dosis på 10 mg/ kg hos børn under 1 år sammenlignet med 7, 2 mg/ l (område 4, 7- 11, 8 mg/ l) hos børn mellem 1 og 5 år.
146 In 10 children with severe sepsis Cmax was 6.1 mg/ L (range 4.6-8.3 mg/ L) after a 1-hour intravenous infusion of 10 mg/ kg in children aged less than 1 year compared to 7.2 mg/ L (range 4.7-11.8 mg/ L) for children between 1 and 5 years of age.
148 6.
6.
Den lille flaske indeholder det aktive stof, og den store flaske indeholder suspensionsvæsken.
The small bottle contains the active substance and the large bottle contains the solvent.
Tryk skruelåget ned iht. vejledningen samtidig med, at det drejes til venstre.
147 Press down according to instructions on the cap while turning to the left.
Luk den store flaske omhyggeligt iht. vejledningen på skruelåget, og ryst den kraftigt i ca.
Reclose the large bottle properly according to the instructions on the cap and shake vigorously for about 15 seconds.
Bare slug det.
Do not chew the granules present in the suspension, simply swallow them.
Luk flasken godt til igen efter brugen iht. vejledningen på skruelåget.
Reclose the bottle properly after use according to the instructions on the cap.
15 sekunder før den bruges.
Shake vigorously each time before use for approximately 15 seconds.
Måleskeen skal bruges til afmåling af den foreskrevne mængde ciprofloxacinsuspension 50 mg/ ml..
The graduated measuring spoon with the markings 1/ 2 is equivalent to 2.6 mL containing 2.5-mL of final suspension and 1/ 1 is equivalent to 5.2 mL containing 5.0 mL of final suspension.
Ikke anvendte lægemidler samt affald heraf bør destrueres i henhold til lokale retningslinjer.
The graduated measuring spoon must be used for measuring the required prescribed amount of Ciprofloxacin oral suspension 50 mg/ mL.
149 < {Fax} > < {Email} >
{Name and address }< {tel }> < {fax }> < {e-mail }>
150 1.
148 1.
Ciprofloxacin Bayer og tilhørende navne (se bilag I) 100 mg/ ml granulat og solvens til oral suspension [Se bilag I – Udfyldes nationalt]
Ciprofloxacin Bayer and associated names (see Annex I) 100 mg/ mL granules and solvent for oral suspension [See Annex I - To be completed nationally]
4. 4 og 5. 1).
The Ciprofloxacin Bayer 100 mg/ mL oral suspension is indicated for the treatment of the following infections (see sections 4.4 and 5.1).
151 • Infektioner i hud og bløddele forårsaget af gramnegative bakterier
• Infections of the skin and soft tissue caused by Gram-negative bacteria
• Malign ekstern otitis
149 • Malignant external otitis
152 Voksne
Adults
Daglig dosis i ml (antal 5 ml måleskeer)
Daily dose in mL
5 ml to gange dagligt op til 7, 5 ml to gange dagligt (én 5 ml måleske to gange dagligt op til halvanden 5 ml måleske to gange dagligt)
(one 5-mL measuring spoonful twice daily up to one and a half 5- mL measuring spoonfuls twice daily)
5 ml to gange dagligt op til 7, 5 ml to gange dagligt (én 5 ml måleske to gange dagligt op til halvanden 5 ml måleske to gange dagligt)
(one 5-mL measuring spoonful twice daily
Kronisk suppurativ otitis media
suppurative
500 mg to gange dagligt op til 750 mg to gange dagligt
daily to 750 mg
7- 14 dage
7.5 mL twice daily
Malign ekstern otitis
otitis media
750 mg to gange dagligt
twice daily
7, 5 ml to gange dagligt (halvanden 5 ml måleske to gange dagligt)
up to one and a half 5- mL measuring spoonfuls twice daily)
28 dage op til 3 måneder
7.5 mL twice daily
153 Indikationer
28 days up to 3
Daglig dosis i mg
external otitis
Daglig dosis i ml (antal 5 ml måleskeer)
daily
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
(one and a half 5-mL measuring spoonfuls twice daily)
Urinvejsinfektioner Ukompliceret (iht. sværhedsgrad cystitis
Uncomplicated
250 mg to gange
250 mg twice
2, 5 ml to gange dagligt op til
2.5 mL twice daily to
og organisme)
daily to 500 mg
dagligt op til 500 mg to gange dagligt
twice daily
50 ml to gange dagligt (en halv 5 ml måleske to gange dagligt op til én 5 ml måleske to gange dagligt)
(half 5-mL measuring spoonful twice daily up to one 5-mL measuring spoonful twice daily)
Hos præ- menopausale kvinder kan der gives 500 mg som éngangsdosis svarende til 5 ml éngangsdosis = én 5 ml måleske som éngangsdosis
In pre-menopausal women, 500 mg single dose may be used corresponding to 5 mL single dose = one 5-mL measuring spoonful as a single dose
5 ml to gange dagligt (én 5 ml måleske to
5 mL twice daily
gange dagligt)
daily
Kompliceret
Complicated
500 mg to
500 mg twice
5 ml to gange
5 mL twice daily to
Mindst 10 dage, i
at least 10 days, it can
pyelonephritis
pyelonephritis
gange
daily to 750 mg
dagligt op til
7.5 mL twice daily
nogle tilfælde kan
be continued for
dagligt op til 7, 5 ml to gange
twice daily
behandlingen
Prostatitis
750 mg to
500 mg twice
dagligt
5 mL twice daily to
fortsætte i længere
2 to 4 weeks (acute)
(én 5 ml
7.5 mL twice daily
end 21 dage (f. eks.
to 4 to 6 weeks
gange dagligt op til halvanden 5 ml måleske to gange dagligt)
(one 5-mL measuring spoonful twice daily up to one and a half 5- mL measuring spoonfuls twice daily)
Prostatitis
(chronic)
500 mg to gange
151 Indications
5 ml to gange 2- 4 uger (akut) til 4- 6 dagligt op til uger (kronisk)
Daily dose in mg
dagligt op til 7, 5 ml to gange
Daily dose in mL
750 mg to
Total duration of
dagligt
(Number of 5-mL
(én 5 ml
treatment
dagligt
measuring spoonfuls)
måleske to
(potentially
gange dagligt op til halvanden 5 ml måleske to gange dagligt) Genitale
including initial parenteral treatment with ciprofloxacin) Genital tract infections
Urethritis og
Gonococcal uretritis and cervicitis
500 mg som
500 mg as a single dose
5 ml som
5 mL as a single dose corresponding to one 5-mL measuring spoonful as a single dose
infektioner
Epididymo-
cervicitis, som skyldes gonokokker
500 mg twice
éngangsdosis éngangsdosis svarende til én 5 ml måleske som éngangsdosis
5 mL twice daily to
154 Indikationer
at least 14 days
Daglig dosis i mg
orchitis and
Daglig dosis i ml (antal 5 ml måleskeer)
daily to 750 mg
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
7.5 mL twice daily
Diaré forårsaget af patogene bakterier, herunder Shigella spp., bortset fra Shigella dysenteriae type 1 og empirisk behandling af svær rejsediaré
caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriae type 1 and empirical treatment of severe travellers' diarrhoea
5 ml to gange dagligt (én 5 ml måleske to gange dagligt)
(one 5-mL measuring spoonful twice daily)
5- 14 dage
5 mL twice daily to
155 Indikationer
152 Indications
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
including initial parenteral treatment with ciprofloxacin) Infections of the skin and soft
Infektioner i hud og bløddele
tissue
5 ml to gange dagligt op til 7, 5 ml to gange dagligt (éno 5 ml måleske to gange dagligt op til halvanden 5 ml måleske to gange dagligt)
(one 5-mL measuring spoonful twice daily up to one and a half 5- mL measuring spoonfuls twice daily)
7 til 14 dage
500 mg twice
Infektioner i knogler og led
7.5 mL twice daily
Højst i 3 måneder
prophylaxis of infections in
Behandling af infektioner eller profylakse over for infektioner hos patienter med neutropeni Ciprofloxacin skal gives sammen med andre antibakterielle stoffer i henhold til officielle retningslinjer.
neutropenic patients Ciprofloxacin should be co- administered with appropriate antibacterial agent(s) in accordance to official guidance.
Behandlingen bør fortsættes i hele neutropeniperioden
entire period of neutropenia
5 ml to gange dagligt (én 5 ml målesske to gange dagligt)
5 mL twice daily (one 5-mL measuring spoonful twice daily)
156 Børn og unge
Children and adolescents
20 mg/ kg legemsvægt to gange dagligt, maksimalt 750 mg pr. dosis, svarende til 0, 2 ml/ kg legemsvægt to gange dagligt, maksimalt 7, 5 ml pr. dosis
20 mg/ kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.2 mL/ kg body weight twice daily with a maximum of 7.5 mL per dose
Komplicerede urinvejsinfektioner og pyelonephritis
treatment (potentially including initial parenteral treatment with ciprofloxacin) Complicated urinary tract infections and pyelonephritis
10 mg/ kg op til 20 mg/ kg legemsvægt to gange dagligt, maksimalt 750 mg pr. dosis, svarende til 0, 1 ml/ kg legemsvægt to gange dagligt til 0, 2 ml/ kg legemsvægt to gange dagligt, maksimalt 7, 5 ml pr. dosis
10 mg/ kg body weight twice daily to 20 mg/ kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.1 mL/ kg body weight twice daily to 0.2 mL/ kg body weight twice daily with a maximum of 7.5 mL per dose
dagligt, maksimalt 500 mg pr. dosis, svarende til 0, 1 ml/ kg legemsvægt to gange dagligt til 0, 15 ml/ kg legemsvægt to gange dagligt, maksimalt 5 ml pr. dosis
weight twice daily with a maximum of 500 mg per dose, corresponding to a 0.1 mL/ kg body weight twice daily to 0.15 mL/ kg body weight twice daily with a maximum of 5 mL per dose
20 mg/ kg legemsvægt to gange dagligt, maksimalt 750 mg pr. dosis, svarende til 0, 2 ml/ kg legemsvægt to gange dagligt, maksimalt 7, 55 ml pr. dosis
20 mg/ kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.2 mL/ kg body weight twice daily with a maximum of 7.5 mL per dose
Indgivelsesmåde
154 Method of administration
I svære tilfælde, eller hvis patienten ikke kan indtage den orale suspension (f. eks. patienter, som får enteral ernæring), bør behandlingen påbegyndes med intravenøs ciprofloxacin, indtil det er muligt at skifte til oral indgift.
In severe cases or if the patient is unable to take oral suspension (e. g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.
2, 5 ml suspension) indeholder ca.
½ measuring spoonful (approx 2.5 mL suspension) provides approx.
5000 mg ciprofloxacin.
500 mg ciprofloxacin.
158 Streptokokinfektioner (herunder Streptococcus pneumonia) Ciprofloxacin må ikke anvendes til behandling af streptokokinfektioner på grund af utilstrækkelig effekt.
Streptococcal Infections (including Streptococcus pneumoniae) Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.
Infektioner i knogler og led Ciprofloxacin bør anvendes i kombination med andre antibakterielle lægemidler, afhængigt af resultaterne af de mikrobiologiske undersøgelser.
155 Infections of the bones and joints Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.
159 Brugen af ciprofloxacin til specifikke svære infektioner, bortset fra behandling af infektionerne nævnt ovenfor, er ikke undersøgt i kliniske studier, og de kliniske erfaringer er begrænsede.
The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited.
Allerede 48 timer efter start af behandlingen med ciprofloxacin kan der forekomme tendinitis og seneruptur (specielt af akillessenen), af og til bilateralt.
156 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
Cytokrom P450 Ciprofloxacin hæmmer CYP1A2 og kan derfor medføre øgede serumkoncentrationer af lægemidler, som gives samtidigt, og som metaboliseres af dette enzym (f. eks. teofyllin, clozapin, ropinirol og tizanidin).
157 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
Ciprofloxacin 100 mg/ ml suspension indeholder 1, 3 g sukrose pr. måleske.
As Ciprofloxacin Bayer 100 mg/ mL suspension contains 1.3 g sucrose per 5-mL measuring spoonful, this has to be taken into consideration in terms of daily intake.
161 Probenecid
Probenecid
Methotrexat
158 Methotrexate
INR skal derfor overvåges hyppigt under og kort efter samtidig indgift af ciprofloxacin og et oralt antikoagulant middel.
It is recommended that the INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with an oral anti- coagulant agent.
162 Clozapin
Clozapine
5. 3).
In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the 159 drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).
Hæmolytisk anæmi Agranulocyto - se Pancytopeni (livstruende) Knoglemarvs - depression (livstruende)
Anaphylactic reaction Anaphylactic shock (life- threatening) (see section 4.4) Serum sickness- like reaction
163 Organklasse
160 System Organ
beregnes fra de foreliggende data) Forstyrrelser i immun - systemet
(cannot be estimated from available data)
Lever og
Hepatobiliary Disorders
Stigning i 164
Increase in transaminases Increased bilirubin
Nedsat
Hepatic impairment Cholestatic icterus Hepatitis
Levernekrose
Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)
Organklasse
161 System Organ
Ikke almindelig ≥ 1/ 1. 000 til < 1/ 100
Uncommon
Sjælden ≥ 1/ 10. 000 til < 1/ 1. 000
Rare
Meget sjælden < 1/ 10. 000
Very Rare
Ukendt hyppihed (kan ikke beregnes fra de foreliggende data)
Frequency
galdeveje
≥ 1/ 100
transaminaser Øget bilirubin
≥ 1/ 1 000 to <
leverfunktion Gulsot
≥ 1/ 10 000 to <
(meget sjældent
< 1/ 10 000
Hepatitis
not known
4. 4)
1/ 100
Petekkier Erythema multiforme Erythema nodosum Stevens - Johnson - syndrom (potentielt livstruende) Toksisk epidermal nekrolyse (potentielt livstruende)
Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening) Toxic epidermal necrolysis (potentially life- threatening)
Muskel - og skeletsmerter (f. eks. ekstremitetssmer - ter, rygsmerter og brystsmerter) Artralgier
Musculoskeletal pain (e. g. extremity pain, back pain, chest pain) Arthralgia
Myalgier Artritis Øget muskeltonus og muskelkramper
Myalgia Arthritis Increased muscle tone and cramping
165 Børn Hyppigheden af ovennævnte artropati refererer til data, som stammer fra studier hos voksne.
Paediatric patients The incidence of arthropathy, mentioned above, is referring to data collected in studies with adults.
Det er indberettet, at en overdosis på 12 g har medført lette toksiske symptomer.
162 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
166 Breakpoints adskiller følsomme stammer fra stammer med intermediær følsomhed og de sidste fra resistente stammer:
Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:
Enterobacteria Pseudomonas Acinetobacter Staphylococcus spp. 1
Enterobacteria Pseudomonas
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
164 Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae * Proteus mirabilis* Proteus vulgaris* Providencia spp.
Den maksimale. serumkoncentration nås efter 1- 2 timer.
165 Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.